ENTX Stock Analysis: Buy, Sell, or Hold?
ENTX - Entera Bio Ltd. Ordinary Shares
$2.86
-0.03 (-1.04%)
▼
5d:
+4.19%
30d:
-2.05%
90d:
+67.25%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Get Alerted When ENTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ENTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ENTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ENTX is currently trading at $2.86, which is considered fair relative to its 30-day fair value range of $2.79 to $3.02.
Technical Outlook: Technically, ENTX is in a strong uptrend. Immediate support is located at $2.57, while resistance sits at $3.03.
Market Sentiment: ENTX scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (11th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.75 (+240.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ENTX is in a strong uptrend. Immediate support is located at $2.57, while resistance sits at $3.03.
Market Sentiment: ENTX scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (11th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.75 (+240.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.79 -
$3.02
Company Quality Score
59/100
(HOLD)
Options IV Signal
11th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 11th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 240.9% below Wall St target ($9.75)
- CAUTION: Bottoming setup, but lagging the sector by 17% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$2.79 -
$3.02
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.31
(10.7%)
Support & Resistance Levels
Support Level
$2.57
Resistance Level
$3.03
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.81
Wall Street Target
$9.75
(+240.9%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 04, 2026 10:20 AM ET
Data refreshes hourly during market hours. Next update: 11:20 AM
Data refreshes hourly during market hours. Next update: 11:20 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 55 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
29 analysts |
$371 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
20 analysts |
$307 | 66 BUY |
|
STOK
Stoke Therapeutics Inc |
STRONG BUY
14 analysts |
$46 | 71 BUY |
|
KURA
Kura Oncology Inc |
STRONG BUY
16 analysts |
$32 | 61 BUY |
